SomaLogic, Inc. is a privately held biotechnology company based in Boulder, Colorado.
CEO Roy Smythe’s presentation at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019 can be downloaded here.
Interested in potential investment opportunities?
SomaLogic Business News
SomaLogic’s clinical laboratory re-accredited by the College of American Pathologists
SomaLogic announced today that its United States clinical laboratory (CLIA laboratory) has been re-accredited by the College of American Pathologists (CAP). The successful renewal of CAP accreditation is based on the results of a recent on-site inspection designed to ensure the highest laboratory standards.
Agilent and SomaLogic sign agreement for supply of custom microarrays
Agilent Technologies, Inc. (NYSE: A) and SomaLogic, Inc. (a privately held biotechnology company) today announced a multi-year supply agreement whereby Agilent will supply customized high-fidelity oligo microarrays for use in the nucleic acid detection step within SomaLogic’s novel SOMAscan assay, a protein measurement platform with applications across basic and clinical research, diagnostics, and pharmaceutical discovery and development.
Melody Harris appointed President of SomaLogic
SomaLogic CEO Roy Smythe, M.D. announced today that Melody Harris has been appointed President of SomaLogic. Ms. Harris joined SomaLogic in April 2018 as Chief Legal Officer from Qualcomm Life, a digital health subsidiary of Qualcomm, where she led global and strategic deals with companies such as Novartis, Philips, Abbvie, United Healthcare, Walgreens, and WebMD as Vice President & Chief Counsel.
SomaLogic announces new collaboration with Janssen Research & Development
SomaLogic, Inc. announced today that it has entered into a collaborative agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the agreement terms, SomaLogic will analyze ~5000 proteins in each of at least 15,000 clinical samples from Janssen to identify and validate protein biomarkers for use by Janssen and SomaLogic in predicting, diagnosing, monitoring, and treating disease.
Proteomic-based diabetes trial launches in UK
SomaLogic is featured prominently in a press release announcing the first patient enrollment in a diabetes prevention study at the Leeds Centre for Personalised Medicine and Health in the UK. The trial uses personalized health insights derived from SomaLogic’s protein measurement technology to advise patients on lifestyle changes to help prevent the onset of type 2 diabetes.
SomaLogic to present at 37th annual J. P. Morgan Healthcare Conference
SomaLogic, Inc., announced today that its new Chief Executive Officer, Roy Smythe, M.D., will present the company’s current status and strategic direction at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California. Dr. Smythe’s presentation, which is included in the Conference’s “Emerging Markets Track,” is scheduled for Wednesday, January 9, 2019 at 3:00 p.m. Pacific Time.
deCODE genetics, an Amgen subsidiary, and SomaLogic announce collaboration to perform large-scale protein analysis of up to 40,000 human samples
deCODE genetics, an Amgen subsidiary, and SomaLogic, Inc. today announced a collaboration that brings together SomaLogic’s expertise in human proteins with deCODE’s expertise in human genetics. The collaboration combines deCODE’s rich data sets with SomaLogic’s leading protein measurement capabilities to enhance the understanding of how human disease and health are mediated through proteins to influence health outcomes.
For older news and press releases, please visit our archive.